Cargando…
Diurnal oscillation of CSF Aβ and other AD biomarkers
To assess stages of Alzheimer's disease (AD) pathogenesis and the efficacy of drugs during clinical trials, there has been immense interest in the field to establish baseline cerebrospinal fluid (CSF) concentrations for potential AD biomarkers such as amyloid-β (Aβ) and tau. Significant within-...
Autores principales: | Lucey, Brendan P., Fagan, Anne M., Holtzman, David M., Morris, John C., Bateman, Randall J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421331/ https://www.ncbi.nlm.nih.gov/pubmed/28478762 http://dx.doi.org/10.1186/s13024-017-0161-4 |
Ejemplares similares
-
Comparison of plasma and CSF biomarkers in predicting cognitive decline
por: Aschenbrenner, Andrew J., et al.
Publicado: (2022) -
Importance of CSF-based Aβ clearance with age in humans increases with declining efficacy of blood-brain barrier/proteolytic pathways
por: Elbert, Donald L., et al.
Publicado: (2022) -
Autosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical AD
por: Schindler, Suzanne Elizabeth, et al.
Publicado: (2015) -
No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF
por: Cicognola, Claudia, et al.
Publicado: (2016) -
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease
por: Brier, Matthew R., et al.
Publicado: (2016)